ENFN250117P12500
- 1.50
- 0.000.00%
Enfusion Newsroom
William Blair Maintains Enfusion(ENFN.US) With Hold Rating
Morgan Stanley Downgrades Enfusion(ENFN.US) to Hold Rating, Raises Target Price to $11.25
Analysts Have Conflicting Sentiments on These Technology Companies: Clearwater Analytics Holdings (CWAN) and Enfusion (ENFN)
Enfusion Cut to Market Perform From Outperform by William Blair
Enfusion Analyst Ratings
William Blair Downgrades Enfusion(ENFN.US) to Hold Rating
Enfusion (ENFN) Was Downgraded to a Hold Rating at William Blair
Stifel Downgrades Enfusion(ENFN.US) to Hold Rating, Cuts Target Price to $11.25
Stifel Downgrades Enfusion to Hold From Buy, $11.25 Price Target
Enfusion Is Maintained at Neutral by Piper Sandler
Piper Sandler Maintains Enfusion(ENFN.US) With Hold Rating, Raises Target Price to $11.5
Enfusion (ENFN) Receives a Hold From Piper Sandler
Stifel Maintains Enfusion(ENFN.US) With Buy Rating, Raises Target Price to $13
Enfusion Analyst Ratings
Stifel Maintains Buy on Enfusion, Raises Price Target to $13
Morgan Stanley Maintains Enfusion(ENFN.US) With Buy Rating, Maintains Target Price $11
Analysts Offer Insights on Technology Companies: Block (SQ), Silicon Laboratories (SLAB) and Enfusion (ENFN)
Stifel Maintains Enfusion(ENFN.US) With Buy Rating, Raises Target Price to $11
Enfusion: Strong Client Acquisitions and Strategic Positioning Drive Buy Rating
William Blair Maintains Enfusion(ENFN.US) With Buy Rating